NeurAxis, Inc. engages in the provision of neuromodulation therapies to address chronic and debilitating conditions in children. The company is headquartered in Carmel, Indiana and currently employs 21 full-time employees. The company went IPO on 2023-08-09. The firm is focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. The company focuses on advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is a food and drug administration (FDA) cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. The Company’s second product, the Rectal Expulsion Device (RED), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge defecating at lower volumes of distension.
Follow-Up Questions
¿Qué tal es el rendimiento del precio de la acción NRXS?
El precio actual de NRXS es de $2.61, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Neuraxis Inc?
Neuraxis Inc pertenece a la industria Health Care y el sector es Health Care
¿Cuál es la capitalización bursátil de Neuraxis Inc?
La capitalización bursátil actual de Neuraxis Inc es $25.7M
¿Es Neuraxis Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 4 analistas han realizado calificaciones de análisis para Neuraxis Inc, incluyendo 2 fuerte compra, 5 compra, 1 mantener, 0 venta, y 2 fuerte venta
